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2: Problem Identification
• Genomic data is increasingly important to patient-centered clinical care and is now often managed by                 
non-geneticists including primary care providers.1
• Identifying genetic factors for disease protection or risk can support clinical decision making for both 
patients and their family members. 
• UVM Health Network Family Medicine practices have recently implemented “The Genomic DNA Test” pilot 
program to begin a concerted effort in offering genetically informed primary care to all patients. 
• The program aims to increase the number of participating primary care 
providers stepwise over time. 
• Some providers may find integration of genomic testing and discussion of 
clinical genetics issues with patients to be challenging, particularly given 
the relatively recent change toward emphasis on these topics in medical 
training curricula.2
3: Public Health Cost and Considerations
• Given the lack of widespread genomic screening in the United States, it is difficult to estimate the public health 
opportunity cost to patients who go without receipt of diagnosis, or one that is late or incorrect.
• Among patients with previously undiagnosed disease, “omics-based” precision medicine in general may yield a diagnosis 
rate of ~35%, with ~1 in 5 newly diagnosed patients receiving new therapeutic recommendations.3
• A 2019 Australian study found population level genomic screening of young adults would be highly cost-effective 
compared to targeted testing. 4 Specifically reducing: 
• Variant-attributable cancers by 28.8%
• Cancer deaths by 31.2 %
• Combined incidence of cystic fibrosis, spinal muscular atrophy, and fragile x syndrome (CF/SMA/FXS) by 24.8%
• According to Healthy Vermonters 2020, 166 in 100,000 Vermonters will die of cancer each year. 5
• 88% of adult Vermonters report having a usual primary care provider. 5
• Providing better supports and education to our genetic testing PCPs could ultimately bolster efforts to                      
expand the Genetic DNA Testing Program and allow us to offer genetic screening to more patients.
4: Community Perspectives
Q: From your perspective, what challenges do you believe medical 
providers face as part of this initiative? 
The challenges are different for each provider type. Primary care 
providers have a less complete grasp of genetics and genetic concepts 
yet are better than geneticists at perceiving opportunities for 
preventative care through a variety of risk assessments and their 
integration with other patient-specific parameters. Genetic experts are 
adept at distilling sometimes complex concepts and describing 
Mendelian risks to patients in longer sessions than is practical for PCPs. 
Transitioning this to primary care while making it practical will require 
novel partnerships that transcend traditional siloed practice paradigms. 
Effecting provider education during patient genomic result handoffs is 
one strategy that needs to be validated.
Dr. Aaron Reiter, MD- Family Physician, UVMMC South Burlington
Q: How do you perceive your role as a family physician with respect to 
genomics screening?
As a steward and educator of patient’s health and with the knowledge 
that 1 in 4 to 1 in 5 of diagnoses being attributable to genes, it is my 
duty to incorporate this field into my clinical repertoire.
Q: What challenges have you encountered incorporating genomic 
screening into your own practice?
Challenges include electronic medical record difficulties, time 
constraints, patient med knowledge limitations and biases…               
clinic resource limitations.
Dr. Robert Wilden, MD- UVMHN Genomic Medicine Program
5A: Intervention and Methodology
• Aims of this project: 
• Gather information from current participating providers on how participation in the genomic 
testing program has influenced their personal knowledge of and comfort with clinical genetics 
topics.
• Identify practice patterns of patient counseling based on specific genetic test results. 
• Intervention:
• Develop a pilot survey for primary care physicians participating in Genomic DNA Testing 
program. Survey questions will aim to assess changes in individual’s clinical genetics knowledge 
base as well as comfort with interpreting the program-provided genetic reports and with 
counseling patients on findings. 
• Review PCP feedback and incorporate into final survey structure and content.
5B: Intervention and Methodology- Pilot Survey
6: Results
• Among the providers asked, feedback was generally very 
positive. Respondents agreed that the survey will be a 
useful tool to expand and improve the pilot program. 
• Suggested revisions largely emphasized revisions for more 
specific question wording. 
• As there are multiple educational aspects to onboarding 
new participating providers, the respondents encouraged us 
to refer to certain learning session and materials (such as 
the GMAP, right) to elicit more specific feedback. 
Image from a provider onboarding video, explaining the Genomic Medicine Action 
Plan (GMAP), a dual patient-provider facing document. The GMAP summarizes next 
steps for both patients and providers following detection of a clinically relevant 
genetic variant. 
7: Limitations and Evaluation of Effectiveness
• Limitations
• Individual PCP feedback might have been 
artificially varied or limited due to different 
levels of personal involvement with the 
program. 
• Patient participation has been relatively limited 
to date, suggesting fewer providers have so far 
encountered many instances of difficult genetic 
counseling conversations. 
• Due to the limited duration of this rotation the 
improved survey has not yet been formally 
deployed to all PCPs.  
• Effectiveness
• Based on positive PCP feedback, we feel this 
project has been successful in its goal of 
developing a comprehensive pilot survey to
evaluate competency concerns of participating 
providers in the Genetic DNA Testing Program. 
• Provider feedback has been useful in improving
survey question clarity and content.
• The survey was well received, and we anticipate 
gathering useful information on ways to improve 
provider support and engagement in this 
program. 
8: Recommendations for Future Interventions 
• Deploy survey to all participating UVMHN Family Medicine providers participating in the Genomic DNA Test pilot 
program. Relevant insights from the survey may include:
• Suggested improvements to educational elements such as onboarding training sessions and patient-provider 
facing clinical action plans.
• Requests for further training or support around specific genetic results
• Ideas for how to better support new PCPs joining the initiative
• Future projects will likely address other strategies for supporting program expansion, such as: 
• Assessing feasibility for inclusion of other specialties (e.g., Ob-Gyn, Outpatient Internal Med)
• Identifying barriers to entry or concerns of providers who elect not to participate
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